title: [Ocular aspergillosis--case report].
abstract: Presence of fungus in the conjunctiva is a constant threat to the eyes, because these microorganisms, defined as opportunistic, may provoke severe ocular infections, in situations as low organic resistance, use of immunosuppressants, antibiotics and epithelial alteration. Our goal here is to report a case of ocular aspergillosis in an immunosuppressed patient where paroxysmal nocturnal hemoglobinuria was diagnosed. A 51-year-old immunosuppressed, thrombocytopenic patient was hospitalized with a diagnosis of paroxysmal nocturnal hemoglobinuria. On examination, she had a visual acuity of 20/40 in the right eye (RE) and light perception in the left (LE). She presented hyposphagma, bilateral conjunctival edema on biomicroscopy and had some multiple and circumscribed conjunctival abscesses in both eyes; clear cornea in both eyes. Fundoscopy of the RE did show any particularity, in the LE there was a smear hemorrhage. Computed tomograph showed a fat periocular infiltration. Magnetic resonance lead to the same finding, compatible with orbital cellulitis. Hemoculture showed Aspergillus growth and direct smears of conjunctival material was negative. There was great improvement while treating her with amphotericin B, but there was complete remission after using 5% natamicyn eye drops. Orbital infections caused by Aspergillus are uncommon, usually appearing in immunosuppressed patients. Frequently they progress insidiously, and can be confounded with other orbital processes. Immunological impairment can inhibit the expression of local and systemic symptoms, resulting in diagnostic confusion. The diagnosis is established by laboratory tests, but culture can be negative in spite of the classical presentation, making the beginning of treatment difficult. In these cases management starts according to the symptoms.
authors.affiliation: Faculdade de Medicina, Universidade Luterana do Brasil.
authors.forename: Patrícia Ioschpe
authors.initials: PI
authors.lastname: Gus
authors.forename: Marcia Cristina
authors.initials: MC
authors.lastname: Bayer
authors.forename: Guilherme Herrmann
authors.initials: GH
authors.lastname: Matos
authors.forename: Cristiane Von Werne
authors.initials: CV
authors.lastname: Baes
authors.forename: Maria Fernanda Melo
authors.initials: MF
authors.lastname: Martins
authors.forename: Júlio
authors.initials: J
authors.lastname: Vargas Neto
authors.forename: Thor Gunnar
authors.initials: TG
authors.lastname: Onsten
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications* / Q000188:drug therapy; D003229:Conjunctival Diseases / Q000188:drug therapy / Q000382:microbiology*; D015821:Eye Infections, Fungal / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D008875:Middle Aged
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B